Biomedical subjects

Dong-mei Lin

Publications and source records attributed to Dong-mei Lin.

10 recordsLinked to original sources

PubMed2006

Tissue microarray analysis reveals a tight correlation between protein expression pattern and progression of esophageal squamous cell carcinoma.

BACKGROUND: The development of esophageal squamous cell carcinoma (ESCC) progresses a multistage process, collectively known as precursor lesions, also called dysplasia (DYS) and carcinoma in situ (CIS), subsequent invasive lesions and final metastasis. In this study, we are interested in investigating the expression of a variety of functional classes of proteins in ESCC and its precursor lesions and characterizing the correlation of these proteins with ESCC malignant progression. METHODS: Fas, FADD, caspase 8, CDC25B, fascin, CK14, CK4, annexin I, laminin-5gamma2 and SPARC were analyzed using immunohistochemistry on tissue microarray containing 205 ESCC and 173 adjacent precursor lesions as well as corresponding normal mucosa. To confirm the immunohistochemical results, three proteins, fascin, CK14 and laminin-5gamma2, which were overexpressed in ESCC on tissue microarray, were detected in 12 ESCC cell lines by Western blot assay. RESULTS: In ESCC and its precursor lesions, FADD, CDC25B, fascin, CK14, laminin-5gamma2 and SPARC were overexpressed, while Fas, caspase 8, CK4 and annexin I were underexpressed. The abnormalities of these proteins could be classified into different groups in relation to the stages of ESCC development. They were "early" corresponding to mild and moderate DYS with overexpression of fascin, FADD and CDC25B and underexpression of Fas, caspase 8, CK4 and annexin I, "intermediate" to severe DYS and CIS with overexpression of FADD and CK14, and "late" to invasive lesions (ESCC) and to advanced pTNM stage ESCC lesions with overexpression of CK14, laminin-5gamma2 and SPARC. CONCLUSION: Analyzing the protein expression patterns of Fas, FADD, caspase 8, CDC25B, fascin, CK14, CK4, annexin I, laminin-5gamma2 and SPARC would be valuable to develop rational strategies for early detection of lesions at risk in advance as well as for prevention and treatment of ESCC.

Adult↗

PubMed2006

[Influences of PC cell-derived growth factor and breast cancer resistance protein on the curative effects of platinum-based chemotherapeutic regimens for advanced non-small cell lung cancer].

OBJECTIVE: To investigate the influences of PC cell-derived growth factor (PCDGF) and breast cancer resistance protein (BCRP) on the curative effects of platinum-based chemotherapeutic regimens for advanced non-small cell lung cancer (NSCLC). METHODS: Specimens of cancer were collected from 87 chemotherapy-naive patients with advanced NSCLC, 61 males and 26 females, aged 42 - 75. Immunohistochemistry was used to examine the expression of PCDGF and BCRP. After the collection of pathological specimens the patients underwent platinum-based chemotherapy. The relationship between the expression of PCDGF and BCRP and the curative effects of chemotherapy was analyzed. RESULTS: The overall response rate (OR) to chemotherapy of the 87 patients was 41.38% (36/87), 36 of the patients were chemosensitive (41.38%), and the other 51 were chemoresistant (58.62%). Forty-six of the 87 patients (52.9%) were PCDGF positive, the PCDGF positive rate of the chemoresistant patients was 74.5%, significantly higher than that of the chemosensitive patients (19.4%, P = 0.000). The patients with high PCDGF expression intensity were all chemoresistant. PCDGF expression was significantly associated with response of chemotherapy (P = 0.000). The overall positive BCRP expression rate was 67.82% (59/87). Of the 51 chemoresistant patients 46 were BCRP positive (90.2%), a rate significantly higher than that of the chemosensitive patients (36.1%, P = 0.000). The intensity of BCRP expression was significantly associated with response to chemotherapy (P = 0.000). CONCLUSION: PCDGF and BCRP may be used as biomarkers to predict the first-line response to chemotherapy in patients with advanced NSCLC.

ATP Binding Cassette Transporter, Subfamily G, Mem↗

PubMed2006

[Prognostic significance of micropapillary pattern in pulmonary adenocarcinoma].

OBJECTIVE: To evaluate the prognostic significance of micropapillary pattern (MPP) in adenocarcinoma of lung. METHODS: Ninety-one consecutively excised cases of pulmonary adenocarcinoma, including follow-up data, were retrospectively studied. These tumors were divided into 2 major groups: those with MPP and those without MPP. The former was further subdivided according to extent of the micropapillary component, as follows: MPP + (constituting 1% to 10% of the tumor), MPP ++ (constituting 11% to 30% of the tumor) and MPP +++ (constituting more than 30% of the tumor). RESULTS: The overall 5-year survival rate was 64.8%. The 5-year survival rates were 88.9% for stage I tumors, 46.2% for stage II tumors, and 23.8% for stage III tumor respectively (P = 0.000). The extent of micropapillary component showed no correlation with tumor stage, size and 5-year survival rate (P = 0.065, 0.358 and 0.206, respectively). On the other hand, the 5-year survival rate was 41.5% for patients in the MPP-positive group (number = 41) and 84.0% for patients in the MPP-negative group (number = 50). The percentage of nodal metastasis in MPP-positive group was also higher than that in MPP-negative group (P = 0.000). In pulmonary adenocarcinoma, this characteristic histology correlated with tumor stage and size, but not with patient's gender and smoking history. Within the same stage, the 5-year survival rates of MPP-positive and MPP-negative groups were as follows: for stage I, 78.6% versus 92.6% (P = 0.1548), for stage II, 30.0% versus 100% (P = 0.0598), and for stage III, 17.7% versus 28.6% (P = 0.4045). CONCLUSIONS: MPP in primary pulmonary adenocarcinoma, even when only constituting a minor component, predicts an aggressive clinical behavior and is associated with poor prognosis. Although it may not be an independent prognostic factor, presence of this histologic pattern should alert clinicians for more active treatment and closer follow up.

Adenocarcinoma↗

PubMed2006

[TPX2 expression and its significance in squamous cell carcinoma of lung].

OBJECTIVE: To study the expression of targeting protein for Xklp2 (TPX2) and its significance in squamous cell carcinoma (SCC) of the lung. METHOD: Two SCC cell lines and 4 immortalized bronchial epithelial cell lines (as a precancerous model) were examined by Western blot for TPX2 expression. Reverse transcription-polymerase chain reaction analysis for TPX2 was also performed using tumor tissues from 21 patients with SCC of the lung. The expression of TPX2 was studied by immunohistochemistry (using tissue microarray) on paraffin-embedded sections of pulmonary SCC and corresponding precancerous lesions from a group of 319 patients. RESULTS: TPX2 was variably expressed in all the cell lines studied. Compared with matched controls using normal lung tissue, high level of TPX2 mRNA was detected in 16 of the 21 SCC tumor tissue samples analyzed. Immunohistochemical study showed that TPX2 was mainly present in tumor tissues but not in normal controls. The expression of TPX2 correlated with tumor grade, stage and nodal status. As for precancerous lesions, the level of TPX2 was also increased, in accordance with the degree of dysplasia. CONCLUSIONS: Expression of TPX2 may play a role in carcinogenesis of bronchial epithelium and tumor progression of pulmonary SCC. It may also represent a potential biomarker for surveillance of SCC of lung.

Blotting, Western↗

PubMed2005

[The diagnostic value of dynamic CT in solitary pulmonary nodules: a prospective study].

OBJECTIVE: To evaluate imaging features of benign and malignant solitary pulmonary nodules (SPN) using dynamic computed tomography (dCT) to improve the accuracy of radiological diagnosis. METHODS: Fifty-one patients with SPN were studied by dCT. In this procedure, a bolus of 100 ml contrast medium was administrated intravenously at a rate of 4 ml/sec. The same-located dynamic scans were carried out from 15 sec to 120 sec following the injection. Time-attenuation curves (TAC) were created according to circular or oval ROI drawn over nodules. Histopathological diagnosis was considered as the golden standard in all patients. Double-blind examination and evaluation were carried out and the data were analyzed statistically with Mann-Whitney U test. RESULTS: Thirty eight cases were diagnosed to be malignant SPN (mSPN) and 13 cases to be benign SPN (bSPN). The benign SPN were further divided into two groups, bSPN(1) consisting 6 cases with chronic pneumonitis, nodular tuberculosis or sclerosing hemangioma and bSPN(2) consisting 7 cases with tuberculoma, pulmonary cyst, pulmonary sequestration or mycosis ball. There were statistically significant differences between mSPN and bSPN(2) in peak heights of enhancement (87.6 HU vs. 57.8 HU, P < 0.01), enhancement values (peak heights- unenhanced CT values, 59.6 HU vs. 11.1 HU, P < 0.01). However, no statistically significant differences of those two values existed between mSPN and bSPN(1). TAC of mSPN reached to peak height more rapidly and remained a plateau. TAC of bSPN(1)s showed similar changes to that of mSPN despite a delayed reach to a peak height or even a descending branch. TAC of the bSPN(2)s was lower and flatter without peak height. If a threshold of 20 HU was taken for dCT, the lesions with < or = 20 HU were diagnosed as benign, and the lesions with > 20 HU were diagnosed as malignant, with a sensitivity of 100%, a specificity of 54.0% and an accuracy of 88.4%. CONCLUSION: (1) Absence of the marked enhancement (< or = 20 HU) in dynamic CT is strongly predictive of benignancy. (2) The peak height and enhancement value of dCT are helpful to differentiate malignant SPNs from benign ones. (3) The TAC configuration is helpful in differentiating malignant SPNs from benign ones. Descending branches could be found in some benign lesions, but not in the malignant ones. The TAC of tuberculoma and mycosis ball is usually relatively low and flat without any peak height.

Adenocarcinoma↗

PubMed2005

[A clinicopathological analysis of gastric lymphoma].

OBJECTIVE: To discuss the clinicopathological features and prognostic factors of gastric lymphoma. METHODS: 83 gastric lymphoma cases were analyzed retrospectively in accordance to the criteria of the new World Health Organization classification for neoplastic diseases of the hematopoietic and lymphoid tissues. The correlations between clinicopathological features, therapeutic measures and survival were discussed. RESULTS: The age of patients ranged from 25 to 77, with a median of 52. The number of males were similar to that of females. There were no specific symptoms. The most common symptoms were stomach ache (60 cases, 72%) or discomfort. The duration of symptoms was often long and with a history of chronic gastric diseases (21 cases, 25%). 13 cases had multiple lesions in the gastrointestinal mucosa. 51 cases (61%) were accompanied by lymph node involvement. According to the new World Health Organization classification for neoplastic diseases of the hematopoietic and lymphoid tissues, 57 cases were extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT)-type (MALT lymphoma), 23 were diffuse large B cell lymphoma accompanying MALT lymphoma, 2 were diffuse large B cell lymphoma and 1 was follicular lymphoma. Of all the cases, 31 were stage I E, 38 stage II E, 8 stage III E and 6 stage IV by the Ann Arbor staging system (1972). The total 5-year and 10-year survival rates were 77.8% and 70.1% respectively, with the mean survival time of 146 months. The 5-year and 10-year survival rates of MALT lymphoma were 77.4% and 72.3%, the 5-year and 10-year survival rates of diffuse large B cell lymphoma accompanying MALT lymphoma were 81.8% and 68.2%, the 5-year survival rate of diffuse large B cell lymphoma was 50.0%. CONCLUSIONS: There are no specific symptoms in gastric lymphoma patients. Extranodal marginal zone lymphoma of MALT-type is the main histopathological type of gastric lymphoma, often accompanied by multiple mucosa involvement and also often accompanied by a history of chronic gastric disease. The lesion is usually localized for a long time, with a very good prognosis. Survival rate has a significant correlation with lymph node involvement and clinical stage. No correlations were found between the survival rates with age, gender, B symptoms, invasive depth of the wall of stomach, the size and range of the tumors or different therapeutic measures.

Adult↗

PubMed2004

[TTF-1 expression and its diagnostic application in lung carcinomas].

OBJECTIVE: To detect the expression of thyroid transcription factor 1 (TTF-1) and study its application in the diagnosis of lung carcinomas. METHODS: Of 134 specimens from lung lobectomy, 105 were primary lung carcinomas including 76 non-small cell carcinomas (NSCLCs), 28 small cell lung cancers (SCLCs) and 1 complex carcinoma (SCLC and SCC), and 29 were metastatic carcinomas. Expression of TTF-1 was detected by immunohistochemistry. The expression level of TTF-1 was graded as, +:6% to 25% of tumor cells positive, ++:26% to 50%, +++:51% to 75%, and ++++:> 76%. RESULTS: The positive nuclear immunoreactivity of TTF-1 was identified in 23 of 28 SCLCs (82.1%), but none in squamous cell cancer (SCC) (P < 0.001). The positive expression rate of TTF-1 in lung adenocarcinomas (ACs) was 73.8% (31/42). There was no correlation between TTF-1 expression and ACs differentiation or ACs subtypes (P > 0.05). All but one (thyroid follicular carcinoma) metastatic ACs were TTF-1-positive. Mesenchymal component and lymphoid or inflammatory cells were consistently TTF-1-negative. CONCLUSION: A significant difference of TTF-1 expression may assist in distinguishing SCLC from SCC, lymphoma or inflammatory lesions. Owing to its restrictive expression in lung tissue, TTF-1 might be used to differentiate primary from metastatic adenocarcinoma of the lung.

Adenocarcinoma↗

PubMed2003

[Use of thyroid transcription factor-1, surfacfant protein-B, cytokeratin 7 and cytokeratin 20 in discrimination between primary and metastatic adenocarcinoma of lung].

OBJECTIVE: To evaluate the utility of thyroid transcription factor-1 (TTF-1), surfactant protein-B, (SP-B) cytokeratin 7 (CK7) and CK20 immunostaining in the discrimination between primary adenocarcinomas and metastatic adenocarcinomas. METHODS: Formalin fixed, paraffin embedded tissue blocks from 42 primary lung adenocarcinomas and 30 metastatic carcinomas resected during operation were immunostained with monoclonal antibodies to TTF-1, SP-B, CK7, and CK20. RESULTS: Positive immunostaining with TTF-1 and SP-B was noted in 74% and 52% of primary lung tumor, respectively. The positive immunostaining and specificity of such a combination for discriminating between primary and metastatic adenocarcinoma were 79% and 94%, respectively. All primary lung adenocarcinomas were CK7 positive, 24 (57%) were CK7 positive/CK20 negative and 18 were CK7 positive/CK20 positive in immunophenotype. Colon and breast were the most common sites of metastasis. All metastatic colorectal adenocarcinomas were CK20 positive, 11 (92%) were CK7 negative/CK20 positive and 1 was CK7 positive/CK20 positive in immunophenotype. The results of cytokeratin immunostaining in the metastatic breast tubular carcinomas were similar to those in the primary lung adenocarcinomas: 4 were CK7 positive/CK20 negative and 4 were CK7 positive/CK20 positive. CK7 positive, and TTF-1 or SP-B positive immunophenotype was seen in 33 (79%) primary lung tumors. A combination of CK7 negative, CK20 positive, and TTF-1 and SP-B negative was highly significantly associated with metastatic colorectal carcinomas compared with either primary lung adenocarcinomas or metastatic breast carcinomas (both P < 0.001). A combination of CK7 positive, CK20 negative, and TTF-1 and SP-B negative was highly significantly associated with metastatic breast carcinomas compared with either primary lung adenocarcinomas or metastatic colorectal carcinomas (both P < 0.001). CONCLUSION: Use of a panel of antibodies including TTF-1, SP-B, CK7 and CK20 is helpful in discriminating between primary and metastatic adenocarcinomas of the lung and suggesting the primary sites of some metastatic adenocarcinomas.

Adenocarcinoma↗

PubMed2003

[Detection of Epstein-Barr virus in T cell lymphoma and clinicopathologic analysis].

BACKGROUND: To study the relationship of Epstein-Barr virus (EBV) and T cell lymphoma. METHODS: Sixty cases of T cell lymphomas were examined for the presence of EBV using in situ hybridization for EBV encoded RNA (EBERs). RESULTS: EBERs were detected in tumor cells in 37(69.8%) of 53 cases with peripheral T cell lymphoma, but in none of seven cases of precursor T lymphoblastic lymphoma. The total detected EBERs were 37(61.6%) in 60 cases of T cell lymphomas. By Revised European-American Lymphoma(REAL) classification, EBERs were detected in 2/2 angioimmuno-blastic T cell lymphoma,17/18 angiocentric lymphoma, 4/6 anaplastic large cell lymphoma and 14/27 peripheral T cell lymphoma, unspecified (51.9%). The frequency of EBERs among the extranodal peripheral T cell lymphoma was higher than the nodal (P less than 0.01) there was no significant correlation with the sex, age and clinical stage. CONCLUSIONS: This study indicated that high incidence of EBV was observed in peripheral T cell lymphoma, with predilection for angiocentric lymphoma and extranodal presentation.

Adult↗

PubMed2002

[Expression and significance of beta-catenin in esophageal carcinoma].

BACKGROUND & OBJECTIVE: Many reports have characterized the aberrant expression of beta-catenin in diverse types of human cancer. To determine whether beta-catenin has possible roles in esophageal carcinogensis, we designed this study to detect the expression pattern of beta-catenin in normal esophageal epithelium and esophageal cancer tissue, then to study the relevance of its expression and localization to tumor differetiation degree and lymph node metastasis. METHODS: By using immunohistochemical staining(SP method), the expression of beta-catenin was detected in 22 normal esophageal tissue slides and 52 esophageal carcinomas. RESULTS: In the 22 normal esophageal tissue, beta-catenin showed high intense expression at the membrane and low intense expression at the cytoplasm. In contrast to the normal tissue, beta-catenin was expressed in the cytoplasma in carcinoma with varied degrees, accompanied by less, or even lost expression at the membrane in cancer samples. In some cases, beta-catenin could be detected in the nucleus. Moreover, the positive rate of beta-catenin expression in cytoplasm was significantly higher in those patients with lymph node metastasis than patients without(P < 0.05). CONCLUSIONS: The aberrant expression of beta-catenin occurred frequently in the esophageal carcinoma, mainly including the translocation of beta-catenin protein from membrane to the cytoplasm and nucleus, and the accumulation of beta-catenin in cytoplasma was overt. And the aberrant expression of beta-catenin protein was statistically correlated to the lymph node metastasis in esophageal cancer.

Adult↗